Oramed Pharmaceuticals Inc. — Director's Dealing 2025

Jan 6, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2025-01-02

Reporting Person: Gabay Avraham (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-02	Common Stock	A	188000	—	Acquired	358040	Direct

Footnotes

F1: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 15,666 over a three year period starting January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.